Lenacapavir: an attractive option, but proceed with caution

Lenacapavir is a potent HIV-1 capsid inhibitor approved as both oral tablets and injectable solution.1 Clinicians are particularly interested in the long-acting injectable formulation, which maintains therapeutic plasma lenacapavir concentrations with subcutaneous injections administered every 6 months.2,3